Breast Center, Peking University Cancer Hospital & Institute, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Beijing 100142, China
Auto-generated profile, based on publicly available information
Yingjian He
Breast Center, Peking University Cancer Hospital & Institute, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Beijing 100142, China
Background: More than 1 million tuberculosis (TB) patients are receiving the standard anti-TB treatment provided by China National Tuberculosis Prevention and Control Scheme (CNTS) in China every year. Adverse reactions (ADRs) induced by anti-TB drugs could both do harm to patients and lead to anti-TB treatment failure. The ADACS aimed to explore ADRs' incidences, prognoses, economical and public health impacts for TB patients and TB control, and build a DNA bank of TB patients. Methods/Design: Multiple study designs were adopted. Firstly, a prospective cohort with 4488 sputum smears positive pulmonary tuberculosis patients was established. Patients were followed up for 6-9 months in 52 counties of four regions. Those suspected ADRs should be checked and confirmed by Chinese State Food and Drug Administration (SFDA). Secondly, if the suspected ADR was anti-TB drug induced liver injury (ATLI), a nested case-control study would be performed which comprised choosing a matched control and doing a plus questionnaire inquiry. Thirdly, health economical data of ADRs would be collected to analyze financial burdens brought by ADRs and cost-effectiveness of ADRs' treatments. Fourthly, a drop of intravenous blood for each patient was taken and saved in FTA card for DNA banking and genotyping. Finally, the demographic, clinical, environmental, administrative and genetic data would be merged for the comprehensive analysis. Discussion: ADACS will give an overview of anti-TB drugs induced ADRs' incidences, risk factors, treatments, prognoses, and clinical, economical and public health impacts for TB patients applying CNTS regimen in China, and provide suggestions for individualized health care and TB control policy.
Background: This study aimed to quantify the frequency and imaging features of new CT-detected pulmonary abnormalities during breast cancer chemotherapy and examine their associations with cumulative cyclophosphamide and paclitaxel exposure. Methods: This single-center retrospective study included 223 patients who underwent an on-treatment chest CT under an early-pandemic infection-control policy. New CT-detected pulmonary abnormalities were defined as new findings on this on-treatment CT that were absent on the pretreatment staging CT. Cumulative cyclophosphamide (C) and paclitaxel (T) doses (mg/m2) were calculated from treatment cycles before the on-treatment CT and dichotomized at 1800 and 960 mg/m2, respectively. Associations were assessed using Firth-penalized logistic regression. Results: New CT-detected pulmonary abnormalities were identified in 34/223 patients (15.2%). Among 25 CT-positive cases with sufficiently detailed CT reports, patchy opacities (14/25, 56.0%) and ground-glass opacities (11/25, 44.0%) were the most frequent findings. Compared with patients with low cyclophosphamide and paclitaxel-equivalent exposure, combined exposure categories showed higher odds of the CT-detected outcome. In the Firth model, cyclophosphamide > 1800 mg/m2 was associated with the CT-detected outcome (adjusted odds ratio (OR) 2.38, 95% CI 1.06–5.71; p = 0.036), whereas paclitaxel-equivalent exposure > 960 mg/m2 (OR 2.46, 95% CI 0.86–6.80; p = 0.092) and age ≥ 60 years (OR 2.08, 95% CI 0.91–4.62; p = 0.083) were not statistically significant. Conclusions: New CT-detected pulmonary abnormalities were common during breast cancer chemotherapy (15.2%). Higher cumulative cyclophosphamide exposure was associated with the CT-detected outcome in multivariable analysis. Prospective longitudinal studies are needed to clarify the clinical significance of these abnormalities and their causality.